Rivaroxaban (Xarelto, BAY59-7939) + Enoxaparin followed by VKA
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Venous Thrombosis
Conditions
Venous Thrombosis
Trial Timeline
Mar 1, 2007 → Apr 1, 2010
NCT ID
NCT00440193About Rivaroxaban (Xarelto, BAY59-7939) + Enoxaparin followed by VKA
Rivaroxaban (Xarelto, BAY59-7939) + Enoxaparin followed by VKA is a phase 3 stage product being developed by Johnson & Johnson for Venous Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00440193. Target conditions include Venous Thrombosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00440193 | Phase 3 | Completed |
Competing Products
20 competing products in Venous Thrombosis